San Francisco: An Indian medical innovation has achieved a major global recognition with a new generation heart stent manufactured in India achieving a lower failure rate in high-risk patients against a US-made international market leader.

At a largely attended global conference of cardiologists, which concluded here on Wednesday, well-known Indian heart specialist, Dr Upendra Kaul, Chairman and Dean of Delhi's Batra Hospital, presented the results of a trial in India named TUXEDO-2, which rigorously compared the new generation Indian-made heart stent, Supraflex Cruz, against the international market leader Xience of the USA.

Conducted across 66 Indian cardiology centres, the trial focused specifically on a highly complex patient population, such as patients with diabetes and advanced mu

See Full Page